Randomised, Open Label, 3-way Cross Over Phase I Study to Investigate the Impact of Concomitant Use of Multiple Doses of Clopidogrel (75 mg qd After a Loading Dose of 300 mg) With Multiple Doses of Dabigatran Etexilate (150 mg Bid) on the Pharmacokinetic and Pharmacodynamic Parameters, and Additionally the Impact of Single Oral Doses of 300 mg and 600 mg of Clopidogrel Administered Under Steady State Conditions of Dabigatran of 75 mg and 150 mg in Healthy Male Subjects
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 44
- 主要终点
- Cmax,ss (maximum measured concentration of the analyte in plasma at steady state)
研究概览
简要总结
The primary objective of the study (Main Part 2) was to investigate whether and to which extent a combination of multiple oral doses (steady state conditions) of 75 mg of clopidogrel q.d. (after a loading dose of 300 mg) and multiple doses of 150 mg of dabigatran etexilate b.i.d. at steady state affects pharmacokinetic and pharmacodynamic parameters of dabigatran etexilate and clopidogrel.
The objective of the preceding Pilot Part 1 of the study was to explore the effect of a single dose of 300 mg clopidogrel administered after multiple doses of 75 mg and 150 mg dabigatran had reached steady state, regarding safety as well as pharmacokinetic and pharmacodynamic parameters.
The Main Part 3 of the study moreover was to compare intra-individually the effects of a single dose of 600 mg clopidogrel with the same dose, 600 mg clopidogrel, given additionally to multiple doses of 150 mg dabigatran in steady state condition with respect to safety and pharmacokinetic and pharmacodynamic parameters.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male subjects according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate), body temperature, 12-lead electrocardiogram, clinical laboratory tests
- •Age ≥18 and Age ≤40 years
- •Body mass index (BMI) ≥18.5 and ≤29.9 kg/m2 (Body Mass Index)
- •Signed and dated written informed consent prior to admission to the study in accordance with GCP and the local legislation.
排除标准
- •Any gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Subjects who in the investigator's judgement are perceived as having an increased risk of bleeding, for example because of:
- •Hemorrhagic disorders or bleeding diathesis
- •Occult blood in faeces or haematuria
- •Trauma or surgery within the last month or as long as an excessive risk of bleeding persists after these events, or planned surgery during trial participation
- •History of arteriovenous malformation or aneurysm
- •History of gastroduodenal ulcer disease, gastrointestinal haemorrhage and haemorrhoids
- •History of intracranial, intraocular, spinal, retroperitoneal, or atraumatic intraarticular bleeding
- •Use of drugs that may interfere with haemostasis during trial conduct (e.g.acetyl salicylic acid or other non-steroidal anti-inflammatory drugs)
- •Relevant surgery of gastrointestinal tract
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of relevant orthostatic hypotension, fainting spells or blackouts
- •Chronic or relevant acute infections
- •History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- •Intake of any medication within four weeks of first dosing
- •Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within four weeks prior to administration or during the trial, especially inhibitors or inducers of P-gp, CYP3A4 CYP2C9 or CYP2C19
- •Intake of medication, which influences the blood clotting, i.e., acetylsalicylic acid, nonsteroidal anti-rheumatic drugs, cumarin etc. within 10 days prior to administration or during the trial
- •Participation in another trial with an investigational drug within one month prior to administration or during the trial
- •Alcohol abuse (more than 60 g/day on a regular basis)
- •Within 5 days of study medication no intake of grapefruit, grapefruit juice, or products containing grapefruit juice, Seville oranges, garlic supplements, or St. John's Worth
- •Blood donation (more than 100 mL within four weeks prior to administration)
- •Excessive physical activities (within one week prior to administration or during the trial)
- •Any laboratory value outside the reference range that is of clinical relevance
- •Inability to comply with dietary regimen of study centre
- •Male subjects do not agree to minimise the risk of female partners becoming pregnant from the first dosing day until 3 months after the completion of the study. Acceptable methods of contraception comprises barrier contraception and a medically accepted contraceptive method for the female partner (intra-uterine device with spermicide, hormonal contraceptive since at least two months)
研究组 & 干预措施
Fixed sequence 1
multiple-dose, fixed-sequence with 2 periods of 4 days separated by a washout period of at least 14 days. A single dose of 300 mg clopidogrel will be given on top of 75 mg or 150 mg dabigatran in steady state.
干预措施: Clopidogrel (Drug)
Fixed sequence 1
multiple-dose, fixed-sequence with 2 periods of 4 days separated by a washout period of at least 14 days. A single dose of 300 mg clopidogrel will be given on top of 75 mg or 150 mg dabigatran in steady state.
干预措施: Dabigatran high dose (Drug)
Fixed sequence 1
multiple-dose, fixed-sequence with 2 periods of 4 days separated by a washout period of at least 14 days. A single dose of 300 mg clopidogrel will be given on top of 75 mg or 150 mg dabigatran in steady state.
干预措施: Dabigatran low dose (Drug)
Crossover
clopidogrel + dabigatran / clopidogrel / dabigatran in randomized order
干预措施: Clopidogrel (Drug)
Crossover
clopidogrel + dabigatran / clopidogrel / dabigatran in randomized order
干预措施: Dabigatran high dose (Drug)
Crossover
clopidogrel + dabigatran / clopidogrel / dabigatran in randomized order
干预措施: Dabigatran low dose (Drug)
Fixed sequence 2
intra-individual comparison with the fixed sequence of a single dose of 600mg clopidogrel alone and the combination of dabigatran 150 mg in steady state plus single dose of 600 mg clopidogrel
干预措施: Clopidogrel (Drug)
Fixed sequence 2
intra-individual comparison with the fixed sequence of a single dose of 600mg clopidogrel alone and the combination of dabigatran 150 mg in steady state plus single dose of 600 mg clopidogrel
干预措施: Dabigatran high dose (Drug)
结局指标
主要结局
Cmax,ss (maximum measured concentration of the analyte in plasma at steady state)
时间窗: up to 19 days
for total dabigatran, clopidogrel and the inactive metabolite SR26334
AUECIPA,0-24 (area under the effect curve of inhibition of platelet aggregation after the first dose of clopidogrel)
时间窗: up to 19 days
AUCτ,ss (area under the concentration-time curve of the analyte in plasma over one dosing interval at steady state)
时间窗: up to 19 days
for total dabigatran, clopidogrel and the inactive metabolite SR26334
AUC0-24,1 (area under the concentration-time curve of the analyte in plasma over one dosing interval after the loading dose)
时间窗: up to 19 days
for clopidogrel and the inactive metabolite SR26334
Cmax,1 (maximum measured concentration of the analyte in plasma after the loading dose)
时间窗: up to 19 days
for total dabigatran, clopidogrel and the inactive metabolite SR26334
Emax,IPA,0-24 (maximum percentage change - compared to baseline - in adenosine diphosphate-induced platelet aggregation after the loading dose of clopidogrel)
时间窗: baseline, up to 19 days
次要结局
- Cavg (average concentration of the analyte in plasma at steady state over a uniform dosing interval)(up to 8 weeks)
- tmax (time from dosing to the maximum concentration of the analyte in plasma)(up to 8 weeks)
- AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)(up to 8 weeks)
- CL/F (apparent clearance of the analyte in the plasma after extravascular administration)(up to 8 weeks)
- Cmax, ss(up to 8 weeks)
- AUCτ,ss(up to 8 weeks)
- AUC0-tz,ss (area under the concentration-time curve of the analyte in plasma from the time point 0 after the last dose at steady state to the last quantifiable analyte plasma concentration within the uniform dosing interval τ)(up to 8 weeks)
- tmax,ss (time from last dosing to the maximum concentration of the analyte in plasma at steady state on day 4)(up to 8 weeks)
- Cmin,ss (minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ)(up to 8 weeks)
- MRTpo,ss (mean residence time of the analyte in the body at steady state after oral administration)(up to 8 weeks)
- Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following an extravascular administration)(up to 8 weeks)
- PTF (peak trough fluctuation)(up to 8 weeks)
- AUECt1-t2 (area under the effect curve (baseline corrected by ratio))(up to 8 weeks)
- AUC0-tz (area under the concentration-time curve of the analyte in plasma from the time point 0 to the last quantifiable analyte plasma concentration)(up to 8 weeks)
- λz (terminal rate constant in plasma)(up to 8 weeks)
- t1/2 (terminal half-life of the analyte in plasma)(up to 8 weeks)
- tz,ss (time of last measureable concentration of the analyte in plasma within the dosing interval τ at steady state)(up to 8 weeks)
- CL/F,ss (apparent clearance of the analyte in the plasma at steady state after extravascular multiple dose administration)(up to 8 weeks)
- MRTpo (mean residence time of the analyte in the body after oral administration)(up to 8 weeks)
- Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)(up to 8 weeks)
- Cpre,ss (predose concentration of the analyte in plasma at steady state immediately before administration of the next dose)(up to 8 weeks)
- tmin,ss (time from last dosing to the minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ)(up to 8 weeks)
- ERmax (maximum effect ratio)(up to 8 weeks)
- tmax (time to maximum effect)(up to 8 weeks)
- Occurence of Adverse Events(up to 13 weeks)
- Assessment of Tolerability by investigator(up to 13 weeks)